Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury

Persephoni backs SelSym Biotech to bring the first shelf-stable, blood-type agnostic hemostatic therapy to the point of injury, expanding trauma access.